[Decrease of the sebum excretion rate and improvement of acne in acneic women treated with the association: cyproterone acetate-ethinyl estradiol (author's transl)].
37 women have received during a total of 429 cycles (mean 12 cycles/patients) an association containing cyproterone acetate 2 mg and ethinyl estradiol 0.05 mg. A marked improvement in the clinical symptoms (acne 35 cases) has been observed. The sequential determination of the sebum excretion rate has been made in the same time (150 measurements) and revealed an important, early and durable decrease in the sebum excretion rate. The respective role of the CA and EE has been analysed in a second trial. It seems that the antiandrogen might play a role in the clinical improvement and in the reduction of the sebaceous flow.
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D012629:Sebum / Q000378:metabolism*; D013997:Time Factors
D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D003534:Cyproterone
Réduction de l'excrétion sébacée et amélioration de l'acné chez des patientes traitées par l'association : acétate de cyprotérone - éthinyl oestradiol.